media1

Zprávy skupiny

  • Aspen generates strong second half cash flows, reducing borrowings
    on 11.09.2019

    Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced reviewed provisional Group financial results for the year ended 30 June 2019. Stephen Saad, Aspen Group Chief Executive said, “Despite the challenging environment, we have achieved most of our short-term goals, including the completion of the disposal… The post Aspen generates strong second half cash flows, reducing borrowings appeared first on Aspen Pharmacare.

  • Aspen hosts more than 120 Mandela Day projects in 40 countries
    on 17.07.2019

    Johannesburg - JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is again reaching out to less fortunate citizens through its Mandela Day projects being hosted on 6 continents. Stephen Saad, Aspen Group Chief Executive Stephen Saad, Aspen Group Chief Executive said, “This is the ninth year that we will participate in Mandela Day, and in 2019 we’ll do so through more than 120 projects in 40 countries. Our Group-wide effort is indicative of our international commitment to socio-economic development and our actions remain closely aligned to our corporate tagline “Healthcare. We Care”. Our intentions are to ensure that our actions aren’t limited to 67 minutes one day a year, but that our projects are sustainable and that partnerships are developed with worthy beneficiaries who we strive to continue to support through related initiatives where possible.” “We remain overwhelmed at the impact that many of our Mandela Day projects have had on communities beyond the annual 18 July event. The majority of these projects are driven by our employees who volunteer selflessly to make a difference in the lives of others and I am humbled and encouraged that many of them become personally involved with their chosen beneficiary on a long term basis. This attitude underscores our corporate ethos of showing respect and care to others while instilling a spirit of dignity in citizens who have been disadvantaged through harsh circumstances that they have not chosen, but are unfairly subjected to. ”  Aspen’s Mandela Day projects cover a broad spectrum of initiatives that include healthcare, nutrition, education, social enhancement and development, infrastructural improvements, animal wellbeing and preserving the environment. There is no discrimination in beneficiary selection with kindness shown to citizens of all ages from all walks of life. “Our sentiments are not driven exclusively by financial contributions but rather through physical actions which enable anyone to give back of their time. Some employees adopt very practical actions such as cleaning the home of a shut-in pensioner or cooking for them, planting mangroves to supplement a threatened ecosystem, improving play areas for children at orphanages, taking wheelchair-bound people on a walk through a park followed by a picnic or simply gifting a meal to a hungry or homeless person,” added Saad. Over the past eight years, the Group has engaged in more than 450 projects in 39 countries which have impacted the lives of some 470 000 beneficiaries. Read more about Aspen’s Mandela Day activities at www.aspenmandeladay.com, follow us on FaceBook, Twitter or LinkedIn and engage on social media via #aspenmandeladay. The post Aspen hosts more than 120 Mandela Day projects in 40 countries appeared first on Aspen Pharmacare.

  • Aspen opens anaesthetic building as part of €100 million investment at its French-based site
    on 18.06.2019

    Johannesburg - JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has expanded its specialist sterile production site at Notre Dame de Bondeville in France to augment the Group’s global manufacturing facilities. Stephen Saad, Aspen Group Chief Executive said, “The new state-of-the-art facility for anaesthetics, together with the new high-speed pre-filled syringe filling and automatic visual inspection lines for thrombosis products, comprise a substantial part of the €100 million investment. The investment in infrastructure at our Notre Dame de Bondeville site will create additional capacity including 80 million individual units of blow fill seal anaesthetics and 180 million pre-filled syringes annually with commercial production expected to begin in 2020. Anaesthetics and thrombosis are two of the Group’s therapeutic focus categories and this investment will support supply sustainability as well as eliminate associated stock constraints being experienced.” To date more than €160 million has been invested at the Notre Dame de Bondeville site and once all the investments are fully operational the site will yield a total capacity of approximately 450 million individual units per year. Anaesthetic products currently manufactured in Sweden and Australia by third party or contract manufacturers will be transferred to Notre Dame de Bondeville and this may generate recruitment opportunities for up to 100 additional employees. The post Aspen opens anaesthetic building as part of €100 million investment at its French-based site appeared first on Aspen Pharmacare.

  • Department of Health and PHEF celebrate investment in human resources
    on 01.05.2019

    The South African National Department of Health (NDoH) and the Public Health Enhancement Fund (PHEF) celebrated their investment in human resources for health in honour of the late Prof Bongani Mayosi on 30 April 2019. The public and private healthcare sector leaders and professionals converged in honour of post-graduate and medical doctors from various healthcare… The post Department of Health and PHEF celebrate investment in human resources appeared first on Aspen Pharmacare.

  • Aspen approved for secondary listing on A2X
    on 25.03.2019

    Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has been approved for a secondary listing on A2X Markets with effect from 1 April 2019. Stephen Saad, Aspen Group Chief Executive said, “We continually strive to identify ways to increase value for our shareholders and the complementary A2X… The post Aspen approved for secondary listing on A2X appeared first on Aspen Pharmacare.